12616 results about "Urea" patented technology

Wood preservative compositions are disclosed. Treatment of lumber, plywood, and other wood products with a novel composition comprising the boron source composition, a melamine binder resin, and a urea casein activator resin protects lumber, plywood, and other wood products from attack by termites, fungi, fire and flame. The preservative can be formed by combining a source of boron such as boric acid and the water-soluble salts thereof, a melamine binder resin, and a urea casein resin. A wood preservative is characterized by a weight ratio of the urea casing activator resin to the melamine binder resin ranging from about 1:20 to 1:4 and a weight ratio of the boron source composition to the melamine binder resin ranging from about 1.3:1 to 9.6:1.

Pharmaceutical, cosmetic and cosmeceutical foamable compositions for topical application, containing, as an active ingredient, urea and/or a derivative thereof, processes of manufacturing these compositions and uses of these compositions in the treatment of various dermatological conditions such as, for example, conditions associated with dry skin and/or scalp.

Apparatus and method for determining at least one parameter, e. g., concentration, of at least one analyte, e. g., urea, of a biological sample, e. g., urine. A biological sample particularly suitable for the apparatus and method of this invention is urine. In general, spectroscopic measurements can be used to quantify the concentrations of one or more analytes in a biological sample. In order to obtain concentration values of certain analytes, such as hemoglobin and bilirubin, visible light absorption spectroscopy can be used. In order to obtain concentration values of other analytes, such as urea, creatinine, glucose, ketones, and protein, infrared light absorption spectroscopy can be used. The apparatus and method of this invention utilize one or more mathematical techniques to improve the accuracy of measurement of parameters of analytes in a biological sample. The invention also provides an apparatus and method for measuring the refractive index of a sample of biological fluid while making spectroscopic measurements substantially simultaneously.

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

An exhaust aftertreatment system comprises an injector for injecting urea water into an exhaust duct, and a denitration catalyst disposed downstream of the injector with respect to a flow of exhaust gas. The exhaust aftertreatment system reduces nitrogen oxides in the exhaust gas by the denitration catalyst while using ammonia produced from the urea water injected from the injector. The urea water is injected along a direction of the flow of the exhaust gas within the exhaust duct, and a porous plate is disposed in multiple stages in a space of the exhaust duct such that droplets of the injected urea water impinge against the porous plate before reaching a wall surface of the exhaust duct. A surface of the porous plate subjected to the impingement of the droplets is arranged to face downstream with respect to the flow of the exhaust gas. Deposition of the urea water is prevented by causing film boiling when the droplets impinge against the porous plate, and the urea water reflected by the porous plate is uniformly dispersed into the exhaust gas. Thus, the urea water is uniformly dispersed into the exhaust gas without increasing a pressure loss of the exhaust gas. The urea water is prevented from depositing on the wall surface and producing a precipitate in the form of a solid.

The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.

The invention belongs to the technical field of preparation of a carbon nano material, and particularly relates to a method for preparing a carbon dot having a high fluorescent quantum yield from citric acid and different nitrogen-containing molecules. The method comprises the following steps: weighing 1-10 mmol of solid citric acid, and dissolving in 10 ml of deionized water; weighing 1-10 mmol of ethylenediamine, ethylamine, propylamine, butanediamine, n-hexylamine, p-phenylene diamine or urea, adding into the citric acid solution, and uniformly stirring; transferring the solution into a hydrothermal or high-pressure microwave reaction kettle, reacting under hydrothermal or microwave conditions, and naturally cooling the reaction kettle to room temperature, thus obtaining a yellow or brown carbon dot water solution; and finally, purifying the carbon dot water solution, evaporating, and drying to obtain pure carbon dot solid powder. The carbon dot solution can send out bright blue fluorescence under the irradiation of a handheld ultraviolet lamp. The invention has wide application prospects in the fields of biological imaging, fluorescent printing and the like.

This patent describes technology for generating ammonia from urea. The method is based on the hydrolysis of an aqueous solution of urea and/or biuret by heating under pressure to form a mixture of ammonia, carbon dioxide and water. The gas mixtures produced are useful for supplying ammonia at controlled pressure and rate of flow for many industrial applications without the risks and hazards associated with the transportation and on-site storage of ammonia, thereby providing a significant safety advantage over present industrial practice.

A method is presented for estimating an amount of ammonia stored in a urea-based SCR catalyst based on a dynamic model of the catalyst. The model takes into account chemical and physical properties of the catalyst, such as catalyst volume, the number of available ammonia storage cites, adsorption and desorption dynamics, as well as sulfur poisoning, thermal aging, and different catalyst operating temperatures, and generates the estimate based on a measured or estimated amount of NOx in an exhaust gas mixture upstream of the catalyst, an amount of reductant injected into the catalyst to facilitate NOx reduction, and on a measured value of NOx in an exhaust gas mixture downstream of the catalyst. The estimated ammonia storage amount is then used to control the amount of reductant injected into the catalyst to maintain desired ammonia storage amount such that maximum NOx conversion efficiency coupled with minimum ammonia slip are achieved.

The present invention provides a polyurethane or polyurethane/urea composition which has a tensile strength greater than 10 MPa, a modulus of elasticity greater than 400 MPa and an elongation at break greater than 30% at a temperature of between 0° C. and 60° C. and at a relative humidity of between 0% and 100%.

The invention further provides uses of the compositions of the invention in biomedical vascular stents, an orthopaedic implant, a drug delivery coating or in tissue engineering.

This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating.

The present invention provides synthetic vaccines against a variety of pathogenic organisms and tumor cells in humans and other mammals based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants. The vaccines can be formulated as a liquid dispersion of polymer particles or molecules in which are dispersed an immunostimulatory adjuvant, such as a TLR agonist, and whole protein or peptidic antigens containing MHC class I or class II epitopes derived from organism or tumor cell proteins. Methods of inducing an immune response via intracellular mechanisms to the pathogenic organism or tumor cells specific for the antigen in the invention compositions are also included.

A reductant delivery unit (10) is provided for selective catalytic reduction (SCR) after-treatment for vehicles. The unit includes a solenoid fluid injector (10) constructed and arranged to be associated with an exhaust gas flow path (14) upstream of a SCR catalytic converter (17). The fluid injector has a fluid inlet (13) and a fluid outlet (15) with the fluid inlet being constructed and arranged to receive a source of urea solution and the fluid outlet being constructed and arranged to communicate directly with the exhaust flow path so as to control injection of urea solution into the exhaust gas flow path. An interface (24) is constructed and arranged to couple the fluid injector to the gas flow path. The interface defines a thermal barrier constructed and arranged to decoupled a body of the injector from exposure to heat in the exhaust gas flow path.

A reductant dosing control system, for use in a Selective Catalytic Reduction (SCR) system of a motor vehicle includes an input receiving a NOx feedback signal from an NOx sensor provided to the SCR system. A base dosing module calculates a required quantity of reductant to inject in front of a SCR catalyst of the SCR system based on the NOx feedback signal. The SCR catalyst has ammonia storage properties. An output signals a reductant metering mechanism to periodically or continuously inject excess reductant based on the required quantity of reductant.

An exhaust emission purifying apparatus has a NOx reduction catalytic converter in an exhaust passage of an engine, for purifying nitrogen oxides in the exhaust gas by reduction with urea aqueous solution; an injection nozzle injecting the urea solution toward an exhaust upstream side of the converter in the exhaust passage; and fins disposed on an exhaust upstream side of an injection position of the urea solution in the injection nozzle, for generating a spiral swirling flow of the gas swirling about a center corresponding to the central axis of an exhaust pipe. The swirling flow generated in the exhaust gas prior to the injection-supply of the urea aqueous solution promotes mixing of the solution with the gas to thereby promote the hydrolysis of the urea solution. And the exhaust gas and ammonia generated from the urea solution are uniformly mixed together.

Topical dermatological compositions comprising urea as an active ingredient, a vegetable oil or a derivative thereof, water, and conventional excipients. These compositions are used for topical medical applications, particularly to treat various skin disorders.

A method is provided for producing ammonia (NH₃) and introducing the produced ammonia (NH₃) into an exhaust gas stream as a reduction means for selectively catalytically reducing nitrogen oxides contained in the exhaust gas stream, which is an exhaust stream generated by the combustion process of a motor, a gas turbine, or a burner. The method comprises feeding dry urea from a supply container in a controlled amount to reactor and subjecting the dry urea in the reactor to a sufficiently rapid thermal treatment such that a gas mixture comprising the reaction products of ammonia (NH₃) and isocyanic acid (HCNO) is created. Also, the method comprises immediately catalytically treating the thus produced gas mixture in the presence of water such that the isocyanic acid (HCNO) resulting from the rapid thermal treatment is converted, via quantitative hydrolysis treatment, into ammonia (NH₃) and carbon dioxide (CO₂).

A selective catalytic reduction (SCR) catalyst control system and method for an engine is disclosed. Urea injection to an SCR catalyst is determined based on an SCR catalyst model, which determines a value of stored NH₃ in the SCR catalyst based on the NO_x engine emission value, the SCR catalyst temperature, the quantity of urea supplied to the SCR catalyst and a pre-determined efficiency of conversion of NO_x gases. A target value of stored NH₃ and the value of stored NH₃ in the SCR catalyst is then used to determine a stored NH₃ differential, which is then used to calculate urea injection.

Compositions, reagent test strips, analyte detection systems and kits of the same, as well as methods for their use in the detection of an analyte in a sample, are provided. The subject compositions are characterized by having a positively charged porous matrix and a urea derivative dye on at least one surface of the matrix, where in many preferred embodiments the urea derivative dye is a negatively charged urea derivative dye. In many preferred embodiments, the subject compositions further include at least one additional reagent member of a peroxide producing signal producing system, e.g., an analyte oxidase and/or a peroxidase. The subject compositions, test strips, analyte detection systems and kits find use in the detection of a wide variety of analytes in a sample, such as a physiological sample, e.g., blood or a fraction thereof.

The invention discloses a carbon nano-dot, and a preparation method and an application thereof, and solves a problem that the application of present nano-dots is restricted because of high preparation cost and easy fluorescent quenching appearance of an aggregate state. According to the invention, the carbon nano-dot having a high fluorescence quantum efficiency is prepared through adopting a polycarboxyl or polyhydroxy contained organic compound, or an amino acid as a raw material, and urea as a surface passivation modification agent, and through a microwave process, and a carbon nano-dot fluorescent ink is prepared through using the carbon nano-dot. The preparation method disclosed in the invention has the advantages of simplicity, low cost and convenient large-scale production; the fluorescent quenching of the prepared carbon nano-dot on the surface of a biological product does not appear, and the highest fluorescence quantum efficiency is 42%; and the prepared carbon nano-dot fluorescent ink is nontoxic, does not generate a precipitate after long-time dispose, and can be applied to the biological imaging field, the biological product identification field, the information storage field, the information encryption field, the false proof field, the illumination display field, the photovoltaic device field and the like.

The present invention provides methods and apparatus for injecting fluid, such as an aqueous urea solution, into an exhaust stream in order to reduce oxides of nitrogen (NOx) emissions from diesel engine exhaust The present invention uses mechanical spill return atomization techniques to produce droplets approximately 50 μm SMD (Sauter mean diameter) or smaller. This size range is appropriate to allow urea to react into ammonia within the residence time associated with an on-road diesel engine. This effect is achieved through the use of a whirl plate having a plurality of whirl slots surrounding an exit orifice of the injector, which produce a high velocity rotating flow in the whirl chamber. When the rotating flow of fluid is passed through the exit orifice into an exhaust stream, atomization occurs from a combination of centrifugal force and shearing of the fluid by air as it jets into the exhaust stream.

The lubricating oil composition of the invention comprises a lubricating base oil with a urea adduct value of no greater than 4% by mass and a viscosity index of 100 or higher, an ashless friction modifier at 0.01-10% by mass and a phosphorus-containing anti-wear agent at 0.01-0.2% by mass as phosphorus, based on the total amount of the composition.

Two lubricating polyurea-ester compositions with high stability and extreme-pressure antiwear performance contain proportionally basic oil, urea-based thickening agent, Ca-based thickening agent and extreme-pressure agent for composition A, or the composition A plus inorganic Ca salt for composition B.

A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.

The invention relates to an oil-in-water nanoemulsion having an oily phase dispersed in an aqueous phase, the oil globules of which have a number-average size of less than 100 nm, containing: (i) at least one amphiphilic lipid comprising at least one nonionic amphiphilic lipid, and optionally at least one ionic amphiphilic lipid, the oily phase and the amphiphilic lipid being present at a content such that the oily phase/amphiphilic lipid weight ratio ranges from 3 to 10, and (ii) at least one hydroxylated urea derivative. Application in cosmetics, dermatology, and ophthalmology.

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C_1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

Cosmetic composition for care and/or makeup, comprising: 1) a liquid fatty phase comprising at least one silicone oil, structured with a gelling system comprising at least one polymer (homopolymer or copolymer) with a weight-average molecular mass ranging from 500 to 500,000, containing at least one moiety comprising: at least one polyorganosiloxane group, composed of 1 to 1000 organosiloxane units in the chain of the moiety or in the form of a graft, and at least two groups capable of establishing hydrogen interactions chosen from among the ester, amide, sulfonamide, carbamate, thiocarbamate, urea, thiourea, oxamido, guanidino, biguanidino groups, and combinations thereof, on condition that at least one of the groups is other than an ester group, the polymer being solid at room temperature and soluble in the liquid fatty phase at a temperature of 25 to 250° C., and 2) at least one film-forming silicone resin, the liguid fatty phase, the gelling system and the film-forming silicone resin forming a physiologically acceptable medium.

A sorbent hemodialysis system includes a dialyzer configured to receive a flow of clean dialysate from a reservoir and to output an unclean dialysate flow. The system also includes a sorbent component having a urease section and a sorbent section through which the unclean dialysate flow from the dialyzer passes, wherein the sorbent component removes urea from the dialysate. The system further comprises a membrane electrolyzer that receives at least a portion of said clean dialysate flow and separates the dialysate flow into an acidic component flow and a base component flow. A mixing conduit combines the base component flow from the membrane electrolyzer and an output dialysate solution from the urease section of the sorbent component to separate the dialysate solution into an ammonia gas amount and ammonia liquid amount. A gas vent is used to vent the ammonia gas amount, and the sorbent section with a suitable amount of zirconium phosphate (ZrP) removes the ammonia liquid amount from the unclean dialysate flow before flowing the clean dialysate to the reservoir. The system can further include a second mixing conduit upstream of the sorbent section of the sorbent component, the second mixing conduit combining the acidic component flow and the ammonia liquid amount in the dialysate solution to increase the pH of the dialysate solution to about 7.5 prior to returning to the reservoir.

The present invention provides novel methods for removal and disposal of ammonia from spent dialysate in a dialysis system. Ammonium ions present in spent dialysate are converted into gaseous ammonia by raising the pH of the spent dialysate solution in a first reactor. Gaseous ammonia diffuses through a semi-permeable hydrophobic membrane at the outlet of the first reactor and into a second reactor via a gas channel. The second reactor converts gaseous ammonia into an ammonium compound for easy disposal.